A case report describes foslevodopa/foscarbidopa infusion in POLG-associated Parkinson’s disease and ALS overlap
Original source
POLG-associated Parkinson's disease-ALS overlap: A novel variant and first reported use of continuous subcutaneous foslevodopa/foscarbidopa infusion in Brait-Fahn-Schwartz disease. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Case report
- Studied in
- Human
A 38-year-old man with POLG-associated parkinsonism followed by amyotrophic lateral sclerosis (ALS) received continuous subcutaneous foslevodopa/foscarbidopa after oral treatment caused motor fluctuations. His motor function was reported to be nearly normal at 12 months. Genetic testing identified a previously unreported POLG variant.
Why this matters
This is a report of device-aided treatment in one person with a rare Parkinson’s disease–ALS overlap syndrome. It may inform clinicians managing similar motor fluctuations, but it does not establish that the infusion treats ALS or benefits other people.
Limitations and context
This is a single-patient case report, not a controlled study. The reported outcome concerns one person and cannot show how effective or safe the infusion is more broadly. The source describes this as the first reported use of this therapy in this condition, so further cases and studies would be needed.